ArticleActive
Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test
A55794
Policy Summary
This document is a response-to-comments notice (Policy A55794) regarding the MolDX EndoPredict Breast Cancer Gene Expression Test and records the comment, notice, and finalization timeline for LCD L37311. It does not itself state clinical coverage criteria or limitations; clinical coverage details reside in the referenced LCD L37311.
Coverage Criteria Preview
Key requirements from the full policy
"Comment period for the MolDX: EndoPredict Breast Cancer Gene Expression Test (LCD L37311) ran from 2017-06-01 through 2017-08-14."
Sign up to see full coverage criteria, indications, and limitations.